Zacks Research Has Bearish Estimate for Bruker Q4 Earnings

Key Points

• Zacks Research has reduced its Q4 2025 earnings estimate for Bruker Corporation from $0.91 to $0.88 per share, impacting the consensus earnings for the full year 2025 which stands at $2.69 per share.
• Several analysts have lowered their price targets on Bruker's stock, with UBS and Goldman Sachs both setting a target of $45.00, reflecting a generally bearish outlook on the stock.
• Bruker has recently declared a quarterly dividend of $0.05 per share, representing an annualized yield of 0.6%, with the ex-dividend date set for September 23rd.

Bruker Corporation (NASDAQ:BRKR - Free Report) - Research analysts at Zacks Research lowered their Q4 2025 earnings estimates for shares of Bruker in a report released on Monday, August 25th. Zacks Research analyst Team now forecasts that the medical research company will post earnings per share of $0.88 for the quarter, down from their prior estimate of $0.91. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker's Q1 2026 earnings at $0.50 EPS, Q2 2026 earnings at $0.46 EPS, Q3 2026 earnings at $0.54 EPS, Q1 2027 earnings at $0.56 EPS and Q2 2027 earnings at $0.60 EPS.

Other equities analysts have also issued reports about the company. UBS Group reduced their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Wells Fargo & Company dropped their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. The Goldman Sachs Group reduced their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Barclays decreased their target price on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Monday, August 4th. Finally, Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the stock a "buy" rating in a research note on Monday, August 4th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $51.30.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $33.59 on Thursday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker has a 1-year low of $30.00 and a 1-year high of $72.94. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of 64.60, a PEG ratio of 2.82 and a beta of 1.16. The business has a 50-day moving average of $38.22 and a 200-day moving average of $40.59.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same quarter in the prior year, the company posted $0.52 earnings per share. The firm's revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Institutional Investors Weigh In On Bruker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its holdings in shares of Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock worth $25,000 after purchasing an additional 487 shares in the last quarter. Pinnacle Bancorp Inc. acquired a new position in Bruker in the first quarter worth approximately $29,000. Huntington National Bank increased its holdings in shares of Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock valued at $30,000 after buying an additional 645 shares in the last quarter. Allworth Financial LP lifted its position in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after acquiring an additional 364 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in shares of Bruker during the 2nd quarter valued at $32,000. Institutional investors own 79.52% of the company's stock.

Insider Activity

In other Bruker news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were purchased at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the transaction, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 27.30% of the company's stock.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's payout ratio is 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.